Welcome to the third quarter 2022 financial results and business update conference call for Yield10 Bioscience. During the call, participants will be in listen only mode. The presenters will address questions from analysts today. To ask a question, simply press star then the number one on your telephone keypad. If anyone should require operator assistance during the conference, please press star zero. As a reminder, this conference call is being recorded. I would now like to turn the conference call over to your host, Yield10 Vice President of Planning and Corporate Communications, Lynne Brum. Thank you, Regina, and good afternoon, everyone. Welcome to the Yield10 Bioscience third quarter 2022 conference call. Joining me on the call today are President and CEO, Dr. Oliver Peoples, Vice President of Research and Chief Science Officer, Dr. Kristi Snell, and Chief Accounting Officer, Chuck Haaser. Earlier this afternoon, Yield10 issued our third quarter 2022 financial results. This press release, as well as slides that accompany today's presentation, are available on the investor relations events section of our website at yield10bio.com. Let's turn to slide two. Please note that as part of our discussion today, management will be making forward-looking statements. These statements are not guarantees of future performance, and therefore, you should not place undue reliance on them. Investors are also cautioned that statements that are not strictly historical constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results to materially differ from those anticipated. These risks include risks and uncertainties detailed in Yield10's filings with the SEC. The company undertakes no obligation to update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this conference call. I'll now turn the call over to Ollie. Thanks, Lynn. Good afternoon, everyone. Thanks for joining our call. As 2022 is progressing, we are making solid progress operationalizing our commercial plan to launch Camelina as a platform crop with a near-term focus on the biofuel feedstock market. Today, we'll provide an update on our recent accomplishments. We'll also provide an update on our growing, contracting, and seed production, winter field trials with a focus on development of herbicide-tolerant Camelina varieties, review key drivers in the biofuel feedstock market, present the third quarter financials, and summarize key milestones. We will then open the call to questions. Let's turn to slide three, Yield10's crop innovation platform. Our innovation platform, the Trait Factory, is centered around the oilseed Camelina to increase carbon capture and direct increased carbon to the seed to produce decarbonizing seed products. We are currently working to establish Camelina as a new platform crop to produce low carbon petroleum replacements and food products. Turn to slide four for Yield10's vision of Camelina. Enabling the large scale production of Camelina grain as a source of decarbonizing seed products requires us to build strong, long-term working relationships with farmers. They, not the oil companies, are the most important players in this new value chain. After all, they own the land. To address grower needs, Yield10 has developed a vision for this crop to enable seamless integration into current cropping and chemical rotations. An integrated herbicide trait package for Camelina is our current key goal. This herbicide trait package will need to include robust tolerance of Camelina to the over-the-top herbicides to maintain grass and broadleaf weed control and tolerance to soil residues from previous crops to secure large acreage production. Lack of broadleaf weed control will not only impact Camelina production, but can increase weed pressure for the next crop in that field, so this is very important to farmers. Camelina is naturally tolerant to Clethodim, a grass herbicide, and some Clethodim-containing products are already labeled for use in Camelina production. As you will see later in this call, Kristi and her team have made great progress developing broadleaf weed control and herbicide tolerance traits in Camelina. In addition to herbicide tolerance, developing new varieties with increased cold tolerance for planting further north and west and early maturing varieties with short cycle times for integration into corn and soybean rotations in the Midwest are also going to be very important to expand rotations. As these traits are developed and commercialized over time, we plan to add in our proprietary traits for increased seed oil and seed yield and provide additional upside to growers and secure even more acres. Turn to slide five, Yield10's business model. Our business model is to develop elite Camelina seed varieties, contract product-production of Camelina grain with farmers, and supply customers in the renewables and food space under offtake agreements. With our current elite varieties progressing towards commercialization and our two proprietary value-added Camelina seed product traits in development, we are positioned to establish and grow a large seed products business. Our lead product is low carbon feedstock oil to meet increased demand from the biofuel sector. Here we are at the early stage of commercial stage and working steadily on partner outreach to secure offtake agreements. We believe this will be followed by the launch of omega-3 Camelina to produce omega-3 oils for nutrition and PHA bioplastic Camelina to supply the growing demand for biodegradable, zero-waste plastic packaging. Combined, these products represent a significant revenue opportunity. Let's turn to slide six, advancing the business. We're making solid progress executing our plan to launch our Camelina seed products business. Our commercial team is engaging regularly with potential supply chain partners to form alliances that will support our capital-light business model. During this third quarter, we secured multiple growers for contract planting of winter Camelina for grain and seed production in areas of southern Canada and Idaho. The plots have been planted and range in size from 30 to 160 acres. We are also ramping up commercial quality winter variety seed production in the winter season in the U.S. and Canada, as well as in contra season in South America for our spring varieties to supply seed for future grain production contracts. As we build our business around Camelina, our research team has done an outstanding job progressing new seed varieties and our pipeline of traits. In 2022, we have executed an intensive effort to field test herbicide tolerance and downy mildew resistance traits. Our elite herbicide tolerant spring Camelina lines have met our performance criteria, and we have selected lead lines for contra-season testing and seed scale-up. By the end of the third quarter, all of our spring field testing sites were harvested. Data is being collected and analyzed by our team, and this will allow us to generate further proof points in our traits and will allow us to identify Camelina, Camelina lines for commercial development. Our 2022/2023 winter field program is underway, with planting completed across sites in the U.S., Canada, Argentina, Uruguay, and Chile. This program is expected to provide us with important data on winter and spring varieties grown in a variety of geographies. Let's turn to slide seven for an overview of our early germplasm. We are establishing our early commercial activities in close cooperation with our growers, with a focus on three early commercial Camelina lines which currently do not have the herbicide tolerant trait package. These lines include the genome edited spring line E3902 and winter lines WDH-2 and WDH-3 that were produced using a breeding procedure. These will be replaced by herbicide-tolerant varieties once they are developed and approved. I'll note here that E3902 was recently designated as non-regulated by regulatory authorities in Chile. In the U.S. and Argentina, it has previously been determined that E3902 does not meet the definition of a regulated article. We plan to apply for this designation for E3902 in Canada once the expected updated CFIA regulations go into effect, which is anticipated to happen soon. Please turn to slide eight for our winter grain contracting and seed production. I'm pleased to say that we have successfully completed our grower contract activities for the winter of 2022/2023. Our growers are clustered in the southern areas of Alberta and Manitoba provinces, with additional growers in northern Alberta and Saskatchewan. If you recall, last year, we conducted seed production of 17 acres on one farm located north of Saskatoon. This seed was cleaned, tested, and bagged, then delivered to the farms from mid-September to October. Admittedly, it was a very tight turn around for our team. The plots we have contracted range from 30 acres to 160 acres, which represents a significant increase in acres from last year. I want to remind you all that we are still in the development stage, where our key goal is to gain experience and build operating capability. We are working closely with the growers participating in our winter program and expect harvest to begin in late summer 2023. Some of the seed harvest is intended for toll crushing and some of it is earmarked for seed production to provide us with seed inventory for growers contracts in 2023, and probably beyond that. In addition to work in seed production in the U.S. and Canada, we also established seed production relationships in Chile and are accessing in-season and contra-season seed production now. I will now pass the call over to Kristi. Thanks, Ollie, and good afternoon, everyone. Let's start with a field report on planting for the winter 2022/2023 season. Please turn to slide nine. Our winter field testing program includes well over 20 sites located in the U.S. and Canada, with additional sites in South America. As the photos on the slide show, the Camelina plants are still small, but will continue to grow until the weather turns consistently cold and there is snowfall. In the spring, when temperatures rise consistently above freezing and the snow melts, the plants will resume growth, flower, and are expected to be ready for harvest in mid to early summer, depending on planting latitude and local climate conditions. The yellow pins on the map in Georgia and Arizona are the winter contra-season locations of our spring camelina herbicide-tolerant field studies for over-the-top weed control. We are conducting further herbicide testing of our lead spring Camelina lines in these studies and are scaling up seed for more extensive planting and trialing in spring 2023. We are also conducting agronomy trials of winter Camelina. The objective of this work is to develop standardized protocols to achieve the best germination, stand establishment, and yields of winter Camelina. This work is taking place across a broad geography, indicated by the blue pins on the map, where we believe planting winter Camelina can be economically viable. Winter wheat is a crop trusted by growers to be extremely cold tolerant. We have planted winter Camelina side by side with winter wheat in certain locations to compare its cold tolerance with this benchmark crop. We have also planted several demonstration fields which will be suitable for hosting grower events in 2023. Let's turn to slide 10. Growers want broadleaf and grassy weed control for Camelina, and we have made significant progress developing and testing weed control in spring Camelina. The timeline on this slide shows our progress towards producing over-the-top spray broadleaf weed control and testing a herbicide for grassy weed control on Camelina. The yellow boxes with green check marks indicate work that has been completed. In 2022, we verified robust broadleaf herbicide tolerance in engineered spring Camelina events, both in the greenhouse and the field. There is a drone photo on the top right-hand corner of this slide showing our spring 2022 research field trial where we achieved robust herbicide tolerance. Engineered lines survived commercial levels of herbicide spray and thrived throughout the growth season while the control lines died. We have obtained good seed yield and oil data for lines from the trial and have selected several commercial oil quality lines to advance. We have also ramped up regulatory efforts for our over-the-top herbicide tolerant lines based on the positive test results we've obtained this year. Our focus over the next few months will be on contra-season field work, indicated by the purple box, with our best lines for product development trials and seed scale-up. In spring 2023, we plan to conduct larger scale field work for product development and herbicide label amendments for Camelina. Let's turn to slide 11. Group two herbicides such as IMIs and SUs are commonly used in some areas that we are targeting for Camelina growth and can persist in soil for months following application. Group two herbicides negatively affect the growth of Camelina. We previously demonstrated that a camelina line in our germplasm collection has tolerance for IMIs in our spring field tests. We are now developing broader Group two herbicide soil residue tolerance for both IMIs and SUs that will expand the acreage accessible to camelina. We have successfully stacked the trait for Group two herbicide soil residue tolerance with the trait for over-the-top herbicide spray tolerance described in the previous slide in our best germplasm. We have also obtained early positive greenhouse results showing tolerance to IMIs, SUs, and our over-the-top herbicide in many lines. Over the next few months, we will perform more extensive greenhouse herbicide tolerance tests on the best lines, indicated by the purple box on the slide. We plan to initiate the regulatory process for these lines in the new year and are on schedule to move plants with stacked herbicide traits into research field trials in spring 2023. As I wrap up, I'd like to acknowledge the Yield10 R&D team. They have put in a tremendous effort generating herbicide tolerant events in Camelina and testing them in the greenhouse and in field trials. This work has positioned us well for further field testing of our best commercial quality Camelina lines in 2023. I'll now hand the call back over to Ollie. Thanks, Kristi, and congratulations to the team for their significant accomplishment executing the spring program and transitioning quickly into planting the winter program. Let's turn to slide 12, biofuel feedstock oil focus. Throughout 2022, there have been several tailwinds for increasing vegetable oil production for decarbonizing biofuels. Production of soybean and canola alone cannot meet this growing demand and still support food production. Therefore, this will require new oilseed crops like Camelina and new crop rotations to use acres which are less productive for soy and canola and double cropping to use land that would otherwise lie fallow. We believe that Yield10 and Camelina can play an important role in this area. Let's turn to slide 13, our business model for the biofuel value chain. The business model we are building for the biofuel feedstock oil market is one where Yield10 plays the role of the Camelina grain originator, producing elite Camelina seed based on our novel genetic traits. We will deploy proprietary Camelina seed on the farmer's land under contract with the right to purchase the Camelina grain harvested. We also plan to engage in offtake agreements for logistics and seed crushing, as well as supply agreements to provide feedstock oil to biofuel players. Let's turn to slide 14, establishing the Camelina value chain. The grower contracts signed in 2022 are an important first step in establishing the Camelina value chain. We expect to learn from their experiences with Camelina over the next several months and continue to build relationships with growers and seed retailers in 2023 to enable planting of more acres for grain production. We envision significantly expanding annual planted acres with the introduction of herbicide-tolerant varieties to fit into crop rotations and for use in cover cropping. Let's now turn to slide 15 for a brief overview of PHA bioplastic and omega-3 programs. Although currently focused on biofuel feedstocks, we continue to make progress on our two future seed product traits. In the PHA bioplastic area, our efforts are focused on optimizing the PHA trait to enable PHA bioplastic production in Camelina seeds, which can be processed to produce three products, PHA bioplastic, biofuel feedstock oil, and protein meal. A prototype Camelina line with our C3015 trait was grown at acre scale this year to produce PHA Camelina grain for process and business development purposes. Prototype PHA winter Camelina lines are being tested for the first time in our winter program. Meanwhile, the R&D team is continuing activities related to trait optimization. Let's now turn to fish oil and the omega-3 markets. Although more a specialty market, Camelina has proven to be an excellent platform for producing omega-3 oils, and there is a large opportunity in the omega-3 fish oil market driven by reduced supply of oil from harvested ocean fish and growing demand in aquaculture feed and nutraceutical markets. We announced today that we have extended our collaboration with Rothamsted. Further, as we advance the program, we have prioritized the development of the EPA component of omega-3 and look forward to deploying it in our elite Camelina with a robust technology package that will combine traits to drive economic performance in the production of high-quality omega-3 oil. Now let's turn to slide 16, the licensing opportunities. We have non-exclusive research license agreements in place with Bayer and GDM, who are testing our traits in soybean. We granted Simplot an extension of the research license for an additional year to study traits in potato. The research license with Forage Genetics for sorghum expired in third quarter as Forage Genetics indicated that they have terminated their sorghum breeding and development program entirely. The research license with Bayer is scheduled to expire in December. We anticipate having a meeting with Bayer to review their most recent field results and to determine their interest in developing traits in soybean. Under license, they have the right to negotiate a commercial license. We are following up on industry interest in oil content traits, including C3007 for soybean and canola, and we're seeking partners to test their traits in corn. The grain platform also represents a unique opportunity driven by interest in identifying novel performance traits. I will now turn the call over to Chuck to discuss third quarter financials. Thanks, Ollie, and good afternoon, everyone. We ended the third quarter with $7.4 million in cash equivalents, and investments. We expect that our cash on hand, together with expected revenue from our current government grant, will support our operations into the first quarter of 2023. We continue to have no debt on our balance sheet. Our net operating cash usage was $2.7 million for the third quarter of 2022, as compared to $2.0 million for the third quarter of 2021. For the full year of 2022, we continue to estimate total net cash usage of $12 million-$12.5 million to fund our operations, including our expanded research and development activities and our preparations for the future commercial launch of our Camelina products. Let's now review the third quarter of 2022 operating results. For the third quarter of 2022, the company reported a net loss after taxes of $3.5 million, as compared to a net loss after taxes of $2.4 million for the third quarter of 2021. Our total research grant revenues in the third quarter were consistent at $111,000, in comparison to $92,000 in the third quarter of 2021. In the third quarter of 2022, R&D expenses were $2.1 million, as compared to $1.6 million in the third quarter of 2021. The G&A expenses were $1.5 million in the third quarter of this year, and that was unchanged from the third quarter of last year. For the nine months ending September 30, 2022, grant revenue was $363 thousand. R&D expenses totaled $5.9 million, and G&A expenses totaled $4.7 million. Our net loss after taxes was $10.3 million. For more details on our financial results, please refer to the earnings release and our 10-Q. Ollie, back to you. Thanks, Chuck. Let's turn to slide 18 in upcoming milestones. As you can see, our technology team has made terrific progress this year executing on the development and scale-up of new Camelina lines for commercial production. We're also very excited to be well-aligned with strong tailwinds in biofuels. As we progress into the end of 2022, we will continue to focus on executing our key milestones, including expanding our commercial activities targeting renewable diesel and aviation biofuel markets, engaging with growers to introduce the benefits of growing Camelina, and continuing to build our differentiated elite Camelina germplasm collection, collecting and analyzing data from our 2022 field testing program, executing in seed production and building inventory for future grower contracts. As we continue to advance the optimization of our PHA bioplastic and progress the commercial launch plan for omega-3 Camelina omega-3 oils. We're very busy in business development by reach to prospective partners across the entire value chain with the goal of executing strategic industry collaborations. We continue to build and expand our intellectual property portfolio. With that, I'd like to turn the call back over to Lynne for questions. Thanks, Ollie. Regina, we're now ready for questions. At this time, if you'd like to ask a question, simply press star then the number one on your telephone keypad. Our first question will come from the line of Anthony Vendetti with Maxim Group. Please go ahead. Yes, thanks. Wanted to focus on the progress you're making in discussions with some of the players in the value chain. You know, it seems like all the developments in terms of Camelina are proceeding according to plan. Can you just tell us about the discussions you're having and where they're at just in general with the players in the supply chain? Yeah. You know, first of all, I appreciate you recognizing just the terrific progress the team has done executing on the commercial side with Camelina. That's obviously a big piece of these discussions also with the third parties. I have to be careful what I say here. We are moving forward with multiple discussions with multiple parties across that value chain at this stage. As you know, Anthony, until one of these things is sort of over the transom signed and announced, there really isn't an awful lot I can say about it. I would say, we're definitely making very good progress. Always difficult to know when one of these things will finally be executed and signed, but obviously, we look forward to communicating that in the future. Okay, great. Just as a follow-up, how much more investment do you think is required to develop new seed varieties? Or, maybe just talk a little bit about that, and then any other options that you're looking at. Besides grant revenue, whether it's licensing or partnership opportunities, in terms of near-term revenue opportunities. Yeah. In terms of our guidance, in terms of money required, and this encompasses the program that we've like laid out and have been executing. You know, we've given guidance between $12 and $12.5. That hasn't really changed at this point. Now obviously Okay. Assuming partnerships kick in, that number could well change because obviously these partners are interested in scale. Of course you would expect other things to change along with that. I would say in terms of grant revenue, we definitely see more opportunities for additional grant revenue and those are things that are being discussed internally. Particularly through this new climate bill, there seems to be some interesting potential there, but we have to wait and see how all that shakes out. In terms of, you know, where we're at with licensing, I think obviously we did mention Bayer coming to the end of its agreement on the C3003 and C3004 traits. Obviously we expect a data readout from Bayer in the not too distant future. As a consequence of that agreement, they do have the right to negotiate a commercial license or an extension of that work. Keep in mind, the Bayer agreement was already expanded. We did add in the C3004 trait after, which was discovered after the C3003. We look forward to the conversation with Bayer and then, obviously if something interesting happens there, then we'll be looking forward to communicating that as well. Okay. Just to clarify on that, they sort of have like the right of first refusal. They get the first opportunity. If something doesn't work out with them, is it correct to say that you have the right to negotiate with someone else? Actually, those agreements, all of those agreements we struck with all of those companies are non-exclusive, and we have the right to negotiate with anybody. I think what we have an obligation to do is to, of course, inform other parties interested in that product, if in fact there is someone, who has entered into definitive, license agreements discussions. Okay. Last question? That's certainly an obligation we have. Okay. Last question before I turn it back to the queue. Can you talk a little bit about the biofuel opportunity, where that's at specifically? Yeah. You know, I would say it's pretty clear to us that when you look at that value chain, and the value chain really starts with new oilseed crops. I mean, there's no question you're gonna see opportunities for increased soy and canola yields, for increased seed oil content in soy and canola. But ultimately, when you start looking at, you know, six billion gallons by 2030, I believe the number is, and that's just for RD, renewable diesel. And you add in three billion gallons for aviation biofuel, and then you see that being boosted to 29 billion gallons by 2050. I mean, it's pretty clear that this is not all gonna come from corn and canola and soybean. It just. There's just no way. Just to give you an example, I think six billion gallons is like adding another 60 million acres of soybean, which is currently 85 million acres. Of course, that 60 million additional acres doesn't really exist. You will see incremental increases on those crops for sure, and you'll definitely see drive towards higher oil and potentially higher yield as well, obviously. I think what it really means is this is gonna have to really rely on new crops that can open up land by offering different rotation benefits to the grower or potentially different timing. That's really the big thing around these oilseed cover crops is basically the ability to use those crops when you would otherwise be leaving the land fallow. Of course, cover crops have these benefits in terms of sustainability, whether it's improving soil carbon, keeping moisture in the soil, reducing nutrient runoff. Ultimately, a cash cover crop like Camelina or other oilseeds like perhaps pennycress and even potentially carinata, if it can be fitted seamlessly into those rotations, offers the grower additional revenue. At the same time as increasing availability of oil for biofuels, it also increases protein production, which is, of course, another area where we see growing demand based on global population growth. Okay, great. Thanks for that. Thanks for that update. Appreciate it. I'll hop back in the queue. Thank you, Tony. Excuse me. Again, to ask a question, simply press star then the number one on your telephone keypad. Our next question will come from the line of Ben Klieve with Lake Street Capital Markets. Please go ahead. All right. Thanks for taking my questions. Oliver, first question for you, is about your comment in your prepared remarks about trying to establish a capital light business model within the Camelina and kind of broad biofuel opportunity. Can you kinda help characterize, you know, how you define capital light business model, you know, for this product, and help us understand the, you know, parts of that model that you would ultimately be responsible for, versus your processing and energy company peers as you see it today? Sure. I mean, there's you know, obviously the piece that you know, we're obviously investing in and intend to own is obviously the genetics. Obviously the traits, the agronomy packages, you know, the manuals for the growers, and ultimately the grower relationships. Those grower contracts, at the end of those grower contracts, of course, those you know, the farmers have got bins full of grain. That grain then would typically be moved to either elevators owned by some of the big you know, crushing companies, and/or shipped directly to some processing facility. Definitely there's a real interest in production close to processing facilities to mitigate some of the logistics and what have you. What we want to avoid, and just let's be very specific about this, is essentially what happened to Calyxt, whereby they went out and contracted acres, and ended up building up a lot of inventory of grain. I think ultimately, I believe they sold somewhere around $40 million worth of grain to ADM, with their high oleic soybean. So obviously we are simply not intending to do that. That doesn't make a lot of sense to us. Right now, what's missing in the biofuel market is new feedstocks. In other words, new sources of oilseed grain that can be processed in existing infrastructure to produce oil and protein, to produce an oil that can actually fit readily into the biofuel markets. Obviously, Camelina already has RINs credits. Obviously it looks like it's gonna have a very attractive CI score. Really the whole issue is the demand is for new sources of oilseed grain. Therefore our view is that, given the supply constraint, given the demand from, sort of both crushers, but as well as basically, the end users, the fuel companies, we should be able to have them underwrite the offtake from the growers so that we get paid when the grain comes out of the farmer's bin and goes to their facilities. That's really the idea here. We should not be building working capital to manage seed inventory. That's not really a business we need to be in. Okay. All right. Very good. That's helpful. Thank you. Have a quick question on a clarifying question on the map that you laid out on slide nine, and then a follow-up. My clarifying question is, you know, there's a pretty dramatic expansion, it appears, of your testing program from last year, and particularly into the Plains and Upper Midwest. And I'm curious, that expansion, is this map entirely kind of the lead varieties or does that expansion also include the, you know, WDH- 2, WDH- 3, and E-3902 that you referred to later in the presentation? Kristi, do you wanna take this? This is the field trial program. The blue pins are our winter lines, and those are our lead WDH-2, WDH-3 that you mentioned. We are also testing some accessions in or other lines in other trials. The yellow ones are the sites of our herbicide-tolerant field trials. Those are spring lines. We've really expanded into the Midwest. This is a good area to rotate with soybean or corn, and we're testing the performance of some of our lines, and we're starting to test the performance of our lines in some of those areas as well. Just so you know, Ben, these are small-scale field plots. These are not large-scale. Most of the large-scale is in Southern Manitoba and Southern Alberta, Southern Idaho. Okay. Okay, perfect. Thank you. Yeah. And then, and then this, um- This is more screening. Got it. Next question, not sure who this is best addressed to, but on herbicide tolerance and, you know, as you look to expand further south, do the herbicide tolerance traits that you are in development now, are those suitable for, you know, the more southern geographies in this map, or are you gonna need to expand your herbicide tolerance to include other chemistries? Yeah. When you lose. really. I'll take this. Okay. Go ahead, Kristi. Okay. Yeah, really the reason we're growing in the south this year is for counter season scale up. This gives us the ability to add another season, so we're taking advantage of the temperature in the south. This isn't necessarily, you know, developing a variety for the southern area. Ollie. Okay. Do you wanna add to that? Yeah. I'll add to that. Ben, I think the question. Basically when you look, the issue really is mainly the soil residues. Obviously, in the corn belt there's a lot of HPPD herbicides used and PPO herbicides. Those are different from the class 2s which are used in the Pacific Northwest. Obviously, you would ultimately want tolerance to one or both of those in the Camelina along with an over the top spray herbicide. That'll be particularly important for integration into a rotation, which would be corn followed by Camelina, then followed by soy. Because again, some of the HPPD residues are going to be a problem in some of those areas. Again, we can't discuss where we're at on that, but obviously that's something that we're very cognizant of and have been working on a plan to address. Okay. All right. Fair enough. You're taking advantage of the temperate winters of Central Minnesota. Got it. Very good. A lot of very good updates coming throughout this call. Congratulations on all the progress. Thanks for taking my questions, and I'll get back in line. Yeah, thanks, Ben. Once again, for any questions, please press star one on your telephone keypad. Again, that is star one. We have no further questions at this time. I'll hand the conference back over to Lynne for any further remarks. Thank you, Regina. I'll now turn the call back over to Olli for his closing remarks. Thanks, Lynn. I'd like to personally thank all of you for joining us on the call tonight, and especially our shareholders for your continued support. In 2022, we've met important milestones, including deploying herbicide tolerant traits in Camelina and engaging growers under contracts as we start to build relationships we rely on to anchor our supply chain for the biofuel market. I want to thank everyone at Yield10 for the contributions that are keeping us on track to reach our goals. I'm particularly proud of the way that this team, small as it may be, has just done a terrific job of executing. Have a nice evening, everyone. Thank you. That will conclude today's call. Thank you all for joining. You may now disconnect.